
    
      Criteria for Evaluation:

      Efficacy: A Response is defined as no evidence of recurrence of a high grade tumor by
      cystoscopy, cytology or if clinically indicated, biopsy.

      Safety: The safety and tolerability of INSTILADRIN will be evaluated based on adverse event
      reports, vital signs, ECGs, clinical laboratory values and results of physical examination.
    
  